FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to recombinant fused proteins, and can be used in medicine. Fusion protein based on a heavy chain of human ferritin, which contains at N-end of protein at least one sequence of splitting matrix metalloproteinase (MMP) and unstructured polypeptide, consisting essentially of proline, serine and alanine (PAS), acting as masking polymer. Nanoparticle consisting of several monomers of said fused protein is also obtained. Nanoparticle or fused protein is a part of the anticancer pharmaceutical composition together with doxorubicin.
EFFECT: invention increases stability of the protein-drug complex.
13 cl, 13 dwg, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| POLYVALENT AND POLYSPECIFIC GITR-BINDING FUSED PROTEINS | 2016 |
|
RU2753439C2 |
| FUSION PROTEIN AND ITS USE | 2020 |
|
RU2811120C2 |
| FUNCTION PROTEIN AND ITS USE | 2019 |
|
RU2800923C2 |
| BINDING OF FUSED PROTEIN TO CD47 PROTEIN AND ITS USE | 2019 |
|
RU2787521C2 |
| IMMUNOGENIC FUSED PROTEIN | 2016 |
|
RU2757426C2 |
| FUSION PROTEIN COMPRISING IL-2 PROTEIN AND CD80 PROTEIN AND ITS USE | 2019 |
|
RU2811541C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING AS AN ACTIVE INGREDIENT A FUSED PROTEIN IN WHICH A TUMOR-PENETRATING PEPTIDE AND AN ANTIANGIOGENIC AGENT ARE FUSED FOR PREVENTING AND TREATING CANCER OR ANGIOGENESIS-RELATED DISEASES | 2016 |
|
RU2727238C2 |
| VACCINATION USING THE ALPHA 3 DOMAIN OF MICA/B FOR CANCER TREATMENT | 2016 |
|
RU2747296C2 |
| IMMUNOMODULATORY FUSED PROTEINS AND THEIR APPLICATION METHODS | 2016 |
|
RU2755227C2 |
| FUSED PROTEIN AND A METHOD OF ISOLATION OF THE FUSED PROTEIN | 1993 |
|
RU2114119C1 |
